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of breast cancer with BMs was derived assuming a steady state approach (with 
incidence equivalent to mortality of metastatic disease), and the average sur-
vival for metastatic breast cancer patients from published literature. Annual SRE 
rates from a European observational retrospective study and the treatment effect 
observed in a head-to-head clinical trial of denosumab versus zoledronic acid 
were used to estimate the total number of predicted SREs by treatment option. 
Country-specific findings from two retrospective studies were used to estimate 
the total number of hospitalisations, inpatient days and direct medical costs 
associated with the management of SREs. Results: Across all countries, the 
estimated prevalence of breast cancer patients with BMs was 87,592 patients: 
Austria, 3,253; Czech Republic, 3,509; Germany, 37,895; Greece, 4,639; Italy, 27,767; 
Spain, 7,553; and Switzerland, 2,975. When denosumab was the selected treat-
ment option, 36,324 SREs were estimated to be avoided per year compared with 
the use of zoledronic acid, which would save 24,110 hospitalisations, 536,551 
inpatient days and 206,605,754€ of direct medical costs (2014 costs in € : Austria, 
23,890,554; Czech Republic, 5,779,856; Germany, 60,659,628; Greece, 15,941,728; 
Italy, 39,998,970; Spain, 17,249,548; and Switzerland, 43,085,469). ConClusions: 
Denosumab’s clinical superiority in the prevention of SREs over zoledronic acid 
could result in significant savings in the number and duration of hospitalisa-
tions, reducing direct medical costs associated with the management of SREs in 
Europe.
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objeCtives: In the UK, PCa is the second most common male cancer resulting in 
over 10,000 deaths annually. LHRH agonists (LHRHa), a type of androgen depriva-
tion therapy, are used to help control PCa and delay progression. LHRHa injections 
are available as 1-, 3- and 6-monthly formulations. Triptorelin is the only LHRHa in 
the UK available as a 6-monthly formulation. DESERVE aimed to collect RWE about 
clinical and practical outcomes for patients starting on, or switching to, 6-monthly 
triptorelin. Methods: A customised data collection programme was designed 
including up to 2 years of data entered retrospectively by physicians from patient 
records at three UK hospitals and prospectively updated over a 5-month period. 
All patients on 6-monthly triptorelin were eligible for entry. The primary outcome 
measure was change in the number of patient–NHS interactions (patient reviews, 
PSA tests and LHRHa injections). Results: 115 patient records were entered; 
records for 88 patients had complete data and were included in the analysis. 47 
were newly diagnosed and initiated on 6-monthly triptorelin; 41 were switched 
from any 3-monthly LHRHa to 6-monthly triptorelin. For switch patients, there was 
a statistically significant reduction in the number of reviews (by 48.4%; p< 0.0001), 
injections (48.4%; p< 0.0001) and PSA tests (29.8%; p< 0.0001) in the 12 months 
following switch versus 12 months before. The total number of patient–NHS inter-
actions was significantly reduced (43.5%; p< 0.0001). At 12 months, median PSA 
was 1.30 ng/mL (23.50 ng/mL at diagnosis) for newly treated patients and 0.24 
ng/mL (0.35 ng/mL at switch) for switch patients. No safety issues were identi-
fied. ConClusions: Patient–NHS interactions were significantly reduced and 
PSA control was maintained with 6-monthly triptorelin vs any 3-monthly LHRHa, 
which translates into NHS savings and improvement in the overall patient experi-
ence. Use of 6-monthly triptorelin may therefore offer advantages over 3-monthly 
formulations for patients, prescribers and payors.
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objeCtives: To provide a scientific basis for the clinical use of drugs and the devel-
opment of government drug policy through pharmacoeconomic study of rituximab 
combined with conventional chemotherapy in treating patients with diffuse large 
B-cell lymphoma. Methods: From the perspective of the health care system, with 
60 years older diffuse large B-cell lymphoma patients in this study, the three-month 
cycle Markov models was established with the time limit of five years and 30 years. 
By controlling treatment, the total direct medical costs of each health status in three 
months associated with DLBCL was got through expert advice and the methods 
Price*Number. The transfer probability between the health statues was calculated 
through survival data of clinical trial; health outcomes within three months of DLBCL 
patients were obtained from literature. On this basis, the pharmacoeconomics eval-
uation was conducted of two programs of rituximab combined with conventional 
chemotherapy and conventional chemotherapy in treating DLBCL. Results: The 
basic analysis showed that: model runs for 5 years, R-CHOP group is more effec-
tive than CHOP group (2.55QALYs> 1.90QALYs), with the higher cost than CHOP 
group (612564.37yuan> 138212.22yuan), the incremental cost-effectiveness ratio 
is 735297.10yuan/QALY.Model runs for 30 years, R-CHOP group is more effec-
tive than CHOP group (4.14QALYs> 2.51QALYs), with the higher cost than CHOP 
group (887550.16yuan> 221662.73yuan), the incremental cost-effectiveness ratio 
is 407808.50yuan/QALY. According to the willingness to pay range (48857.55yuan-
146572.7yuan) which was set by China’s per capita GDP, R-CHOP program has higher 
cost and better effect, but does not have cost-effectiveness advantage in five or 
thirty years. ConClusions: Based on the research’s results and China’s current 
situation, we can say that rituximab combined with conventional chemotherapy 
for DLBCL patients compared with single conventional scheme does not have the 
cost-effectiveness advantage in 5 or 30 years.
objeCtives: Thromboembolic (TE) events are a major complication of polycythemia 
vera (PV). Little is known about economic implications of TE events in such patients. 
This study aims to assess the incremental health care resource use (HCRU) and 
costs associated with PV and post-PV TE events in a real-world patient popula-
tion. Methods: We conducted a retrospective cohort study of PV patients aged < 65 
years enrolled in employer-sponsored commercial health plans in the US. Annual 
all-cause and PV-related HCRU and costs (adjusted to 2014 US dollars) among PV 
patients were compared against non-PV comparison subjects who were propen-
sity-matched on demographics and comorbidities. For patients with a post-PV TE 
event, average 12-month costs following index TE event were assessed. Costs were 
also analyzed in a subgroup receiving hydroxyurea treatment. Results: A total 
of 12,990 PV patients (diagnosed 2000-2012) were included. HCRU was generally 
higher among PV patients versus matched comparison subjects, with largest dif-
ference observed for outpatient hospital visits (90% vs. 70% respectively, p < 0.0001). 
Mean all-cause annual total costs among PV patients were significantly greater 
than comparison subjects ($17,418 vs. $10,501, P < 0.0001). In a subset of patients 
treated with hydroxyurea (n= 774), mean PV-related annual total costs ($7,657) were 
nearly 3 times higher in contrast to costs observed among all PV patients ($2,535). 
Among PV patients experiencing TE events, mean 12-month all-cause costs were 
more than 4 times higher than among those with no TE event ($48,211 vs. $10,958, 
P < 0.0001). ConClusions: Total all-cause HCRU and costs in PV patients were 
substantially higher compared to a matched non-PV comparison group. Patients 
receiving hydroxyurea had higher costs, potentially reflective of inherently more 
severe disease in this patient subgroup. Costs were also substantially higher among 
patients experiencing post-PV TE events, highlighting the importance of treatments 
that may reduce cardiovascular complications in patients with PV.
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objeCtives: To estimate the total number of skeletal-related events (SREs), the 
associated hospital burden and direct medical costs when denosumab is used 
instead of zoledronic acid in patients with prostate cancer (PC) and bone metasta-
ses (BMs). Methods: A model was developed using the following data: country-
specific PC mortality data from the World Health Organization or local registries; 
the proportion of PC patients with BMs from published literature; the prevalence 
of BMs in the metastatic PC population assuming a steady state approach (with 
mortality of metastatic disease equivalent to incidence); and the average survival 
of metastatic PC patients from published literature. Both the annual SREs rates 
from a European observational study and the treatment effect of denosumab 
versus zoledronic acid reported in a head-to-head clinical trial were used to 
predict the total number of SREs by treatment. Country-specific data from two 
multi-country observational studies were used to estimate the total number of 
hospitalisations, length of inpatient stays and direct medical costs associated with 
the management of SREs. Results: Of the 67,375 patients with PC and BMs, the 
prevalence by country was: Austria, 2,447; Czech Republic, 2,707; Germany, 28,447; 
Greece, 3,888; Italy, 16,683; Spain, 9,428; and Switzerland, 2,776. If denosumab was 
the selected treatment option for all patients, an estimated 38,690 SREs per year 
could be avoided, leading to 14,599 fewer hospitalisations, a reduction of 270,007 
inpatient days, and 155,213,984€ of savings in direct medical costs per year. The 
2014 costs saved by country were: Austria, 19,919,201€ ; Czech Republic, 4,095,737€ ; 
Germany, 36,895,464€ ; Greece, 18,504,154€ ; Italy, 24,529,334€ , Spain, 18,931,728€ and 
Switzerland, 31,338,666€ . ConClusions: Denosumab can result in significant 
reductions in the number and length of inpatient stays of PC patients with BMs, 
leading to substantial savings of direct medical costs associated with the manage-
ment of SREs in each of the 7 European countries.
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objeCtives: To estimate the total number of skeletal-related events (SREs) 
prevented, related hospital burden and direct medical expenditure when deno-
sumab is used instead of zoledronic acid for SRE prevention in seven European 
countries. Methods: A model was developed combining country-specific breast 
cancer mortality data from the World Health Organization or from local regis-
tries, the proportion of metastatic breast cancer patients with bone metastases 
(BMs) at high risk of developing SREs from published literature, the prevalence 
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marketed lapatinib, which has the highest consumption among the most expensive 
drugs in Norway and Slovakia. ConClusions: Countries with lower GDP have less 
availability of anticancer medicines in amount and in quantity. Countries with 
lower GDP must control the usage of drugs for malignancy treatemnt if they want 
to allocated their resurses for treatment of other diseases as well.
PCN305
PAtieNt CouNt ForeCAStS oF AdvANCed NoN-SMAll Cell luNg CANCer: 
reSultS FroM the uk, gerMANy, FrANCe, itAly ANd SPAiN (eu-5)
Kish JK1, O’Day K1, Manley-Daumont M2, Campbell DJ1, Penrod J3
1Xcenda, Palm Harbor, FL, USA, 2Bristol Myers Squibb, Paris, FL, USA, 3Bristol Myers Squibb, New 
Brunswick, NJ, USA
objeCtives: Accurate estimates of the number of advanced (Stage IIIb and Stage 
IV) non-small cell lung cancer (ADV-NSCLC) patients are needed to estimate the 
potential clinical and economic outcomes of new targeted therapies for ADV-NSCLC. 
The objective of this study was to forecast counts of squamous/non-squamous 
cell patients eligible for first- through third-line treatment yearly from 2015-2019 
in EU countries. Methods: Segmented linear regression (“joinpoint”) was used 
to forecast age- and gender-stratified lung cancer incidence rates from histori-
cal (year 2000+) population-based cancer registry data over the next five-years. 
Yearly incident case count totals by country were apportioned according to NSCLC 
morphology and stage at diagnosis. Early to advanced stage progression rates were 
estimated over a 10-year interval. Advanced patients receiving systemic treat-
ment were further stratified by histology and line of treatment to obtain counts. 
A probabilistic sensitivity analysis (PSA) was used to estimate variability in the 
patient counts. Results: By histology, the forecasted number of squamous and 
non-squamous ADV-NSCLC patients receiving first-line treatment in 2015 were: 
Germany = 13,300 and 21,200; UK = 8,400 and 21,300; France = 11,800 and 18,800; 
Italy = 7,600 and 20,500; Spain = 7,100 and 11,400. Combined across both histolo-
gies, the numbers of patients receiving second- and third-line treatment in 2015 
were: Germany = 17,400 and 4,400; UK 15,500 and = 4,000; France = 15,500 and 4,000; 
Italy = 14,600 and 3,800; Spain = 9,400 and 2,400. The projected numbers of deaths 
due to ADV-NSCLC in 2015 were: Germany = 35,300; UK = 27,700; France = 30,800; 
Italy = 27,400; Spain = 19,500. ConClusions: These results represent the first 
published data to estimate the current and future number of patients eligible for 
targeted ADV-NSCLC therapies in the EU-5. Despite declining incidence trends, there 
remains a significant unmet clinical need for ADV-NSCLC treatments to reduce 
high mortality rates.
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objeCtives: Patient access schemes (PAS) give UK patients access to medicines not 
normally funded by the National Institute for Health and Care Excellence (NICE) and 
balance company profits and competitiveness with government interests to ensure 
availability of medicines at reasonable prices. In April 2011 the NHS payer funded 
Cancer Drugs Fund (CDF) was introduced in England to further improve access to 
life saving cancer medicines not approved by NICE. The objective of this study was 
to determine whether access to new, non-NICE funded oncology medicines contin-
ues to rely on the relatively cost effective PAS or increasingly depends on the more 
costly NHS payer funded CDF. Methods: A search was undertaken for all NICE- or 
Scottish Medicines Consortium (SMC)-approved HTAs incorporating a PAS (PAS-
HTAs) 4 years before and after introduction of the CDF. In addition, all medicines 
approved for use under the CDF were identified. Results: Fifty five of 128 NICE- or 
SMC-approved PAS-HTAs between October 2007 and June 2015 were in oncology. Of 
these, 10 NICE and 4 SMC PAS-HTAs had been approved prior to, whereas 17 NICE 
and 24 SMC PAS-HTAs had been approved after introduction of the CDF, amount-
ing to an almost 6-fold increase in SMC PAS-HTAs but a less than 2-fold increase 
in NICE PAS-HTAs over a similar period. However, 7 oncology medicines receiving 
HTA approval by the SMC but not NICE were included in the May 2015 CDF list of 
approved medicines. ConClusions: Since the introduction of the CDF, there has 
been a discrepancy between the number of PAS-HTAs in cancer treatments between 
NICE and the SMC. For selected medicines, the CDF appears not to have improved 
access to oncology products as part of PAS-HTAs but rather lead to increased costs 
to health service payers.
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objeCtives: The mode by which patients receive information may impact their 
perception of drugs and consequently their compliance. This study aims to meas-
ure how different presentation factors (format - textual, tabular, graphical; order 
of presenting risks and benefits) and patient characteristics can impact percep-
tion of a drug’s risks and benefits. Methods: Data were collected via an online 
questionnaire presenting two drug options to patients in three therapeutic areas: 
atrial fibrillation, breast cancer, diabetes. Two questions were asked on the safety 
and the willingness to take the drug. A novel Generalized Estimating Equation 
method for correlated multinomial data proposed by Touloumis et al., 2013 was 
used to create an ordinal cumulative link model for the questions on perception. 
Factors controlled for were: presentation format, order of presentation of risks and 
benefits, comprehension of drug’s effects by the subject, order of presentation of 
different formats, current mood, and demographic characteristics. Results: Drug 
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objeCtives: The aim of this study was to assess basal cell carcinoma (BCC) 
prevalence in real practice, and to calculate the related healthcare resources 
consumption. Methods: An observational retrospective cohort analysis based 
on administrative databases of three Italian Local Health Units was conducted. 
Beneficiaries who have been hospitalised for BCC (ICD-9 code 173) or with a histo-
logical diagnosis (ICD-O M8090/3-8093/3) from January 1st, 2009 to December 31st, 
2013 - index date - were included. Patients were characterised back to Jan 2009, and 
followed up till the end of the observation period (Dec 2013) to assess healthcare 
resource consumption. Results: According to preliminary findings on around 
550’000 beneficiaries, BCC prevalence through discharge diagnosis was around 6 
cases every 10.000 patients/year; considering also pathological anatomy database, 
10 cases of BCC every 10.000 patients/year were reported. Advanced patients (aBCC) 
were reported to be around 4%, most of them defined according to the following 
criteria: two surgical excisions on the same side and at least one subsequent proce-
dure (surgery, radiotherapy, photodynamic therapy or imiquimod), 0,3% of enrolled 
patients had metastasis.During follow-up, ambulatory surgery was performed in 
63.5% of advanced patients, around 1.6% underwent radiotherapy and 38.1% of 
them had at least one hospital admission; imiquimod was prescribed in 11.1% of 
patients. Yearly aBCC patients resource expenditure was around 404€ for hospitali-
sations - index costs excluded - 32€ for ambulatory care and 77€ for drugs (anti-
inflammatories, antibiotics and topic drugs; 16€ for imiquimod). ConClusions: As 
BCC patients are reported to have a low recurrence of hospitalisations, discharge-
based analysis would underestimate real prevalence. With pathological anatomy 
database, this study estimated 0.4 advanced BCC cases/10’000 beneficiaries/year. 
Healthcare consumption in this sub-population was driven by hospitalisations and 
ambulatory costs due to surgical excision
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objeCtives: Vandetanib, approved in 2012 in Canada, is indicated for the treatment 
of advanced medullary thyroid cancer. QTc-prolongation or torsade de pointes is 
considered in the risk management plan as an identified risk. To minimize this risk 
a restricted distribution program (RDP) has been implemented. Although shown 
effective, there are limited data on its associated burden to patients, health care 
professionals and the healthcare system. The objectives of the present study are 
to evaluate qualitatively and quantitatively the burden associated with the differ-
ent components of the vandetanib RDP and, to determine the economic impact of 
the program for the healthcare system. Methods: A mixed method evaluation 
has been used. Burden was determined by comparing prescribing and monitoring 
practices under the RDP with those that would have been observed in the absence 
of the RDP. Data on healthcare usage were collected through interviews conducted 
in convenient samples of HCPs (prescribers, pharmacists and nurses) either exposed 
to the RDP or not yet certified for the vandetanib RDP (i.e., unexposed) but familiar 
with the treatment of medullary thyroid cancer. A mapping of patient journeys, with 
and without the RDP, was developed to identify major components of the program. 
An economic evaluation, considering the perspective of the third party payers com-
pleted this analysis. Avoidable costs corresponded to those associated with activi-
ties deemed redundant with routine oncology care. Results: Major components 
of the vandetanib RDP have been identified as well as areas of redundancies with 
standard oncology care. For each component, the qualitative burden for HCPs and 
ultimately patients was determined along with its associated costs considering 
the third party payers perspective. ConClusions: Risk minimisation measures 
should avoid duplication of efforts and loss of economic resources. Evaluation of 
burden, key to optimize the effectiveness of risk management plans, should be 
conducted systematically.
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objeCtives: Consumption and expenditure of drugs for malignancy varies between 
countries. One of the main reason is the high price of this innovative drugs. 
Developed countries have more resources for the treatment of malignant diseases 
and better access to expensive drugs than countries with midle income. Methods: 
We compared the data on expenditure and consumption of innovative anticancer 
drugs in middle income country Serbia (13,020 USD), and high income country 
with different GDP: Slovakia (26,497USD) and Norway (64,406 USD) during the year 
2012. Consumption data were expressed in grams of active ingredient per million 
in one year, expenditure in EU. Results: In Norway 144 drugs for malignancy is 
on market, while in Serbia only 92 drugs are available for ttreatemnt of malignancy. 
In Norway in year 2012 440 million eur was spent for drugs for malignancy, or 
about 80 million euros per million inhabitans. Slovakia had more than half lower 
consumption of anticancer medicines, 190 million euros, or about 37 million euros 
per million inhabitants. In Serbia only 73 million euros was spent for anticancer 
drugs, or about 10 million euros per million ihabitants, which is much less com-
pared to the other two countries. Data on consumption 10 most expensive oncology 
drugs, show that the least of these drugs are consumed in Serbia when comparing 
to Norway and Slovakia. Among them, the most frequently used drug in Serbia 
is trastuzumab(treatment of metastatic breast cancer). For this indication is also 
